⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28324778 | 0.75 | ALDH1A1 (0.41) | — | |
| SCHEMBL29642664 | 0.74 | — | — | |
| SCHEMBL9937744 | 0.74 | — | — | |
| SCHEMBL31095086 | 0.74 | — | — | |
| SCHEMBL15903667 | 0.72 | — | — | |
| SCHEMBL26091 | 0.69 | — | — | |
| SCHEMBL7631751 | 0.67 | — | — | |
| SCHEMBL448551 | 0.65 | — | — | |
| SCHEMBL9938341 | 0.65 | — | — | |
| SCHEMBL7106016 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456780-A2 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-30 | — | — | EP | claimed |
| WO-2026054676-A1 | METHOD FOR PRODUCING (10S, 13S, 16R, 17R)-17-HYDROXY-10,13,16-TRIMETHYL-17-PROPANOYL-7,8,12,14,15,16-HEXAHYDRO-6Н-CYCLOPENTA[A]PHENANTHRENE-3-ONE | ГУРОВ, Дмитрий | 2026-03-12 | — | — | WO | disclosed |
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4164743-A2 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220218734-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING UVEAL MELANOMA | UNIV GENT (BE) | 2022-07-14 | — | — | US | disclosed |
| US-11249091-B2 | Detection of glucuronidated and 3-bromotyrosine | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2020239685-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING UVEAL MELANOMA | UNIVERSITEIT GENT (BE) | 2020-12-03 | — | — | WO | disclosed |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-2948152-A2 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | Sphaera Pharma Pvt. Ltd. (IN) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014115167-A2 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | SPHAERA PHARMA PVT. LTD. (IN) | 2014-07-31 | — | — | WO | disclosed |
| EP-2651916-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |